$1,001 - $15,000Reported range · official band, not an exact amount
9 different filers disclosed LLY within 90 days. Disclosed 28 days after the transaction; reported as an official range, not an exact amount.
Traded Dec 24, 2025 · Filed Dec 29, 2025
A big owner of Eli Lilly sold $2.85M of Eli Lilly shares. Nobody planned it ahead of time.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$2,852,920
Shares × reported transaction price
55 days after results of Oct 30, 2025, 42 days before results of Feb 4, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $1,076.98 on Dec 24, 2025, within 3% of its 52-week high, after a 9% rise over the previous 30 trading days
52-week range $625.65 (Aug 8, 2025) to $1,109.94 (Nov 25, 2025), 93% of the way up, from 250 adjusted closes. 30 trading days earlier: $988.62 on Nov 11, 2025. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
FDA approved Mounjaro on Dec 19, 2025, 5 days before this trade.
New use approved (efficacy supplement). Active ingredient: Tirzepatide. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | -1.4% | +0.7% | -2.1% |
| 30 days | -5.2% | +1.0% | -6.2% |
| 90 days | -17.9% | -8.0% | -9.9% |
| 180 days | +13.9% | +7.9% | +6.0% |
Past results only. Not a forecast.
9 different filers disclosed LLY within 90 days. Disclosed 28 days after the transaction; reported as an official range, not an exact amount.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.